241 related articles for article (PubMed ID: 18713982)
1. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
Tinder TL; Subramani DB; Basu GD; Bradley JM; Schettini J; Million A; Skaar T; Mukherjee P
J Immunol; 2008 Sep; 181(5):3116-25. PubMed ID: 18713982
[TBL] [Abstract][Full Text] [Related]
2. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Mukherjee P; Basu GD; Tinder TL; Subramani DB; Bradley JM; Arefayene M; Skaar T; De Petris G
J Immunol; 2009 Jan; 182(1):216-24. PubMed ID: 19109152
[TBL] [Abstract][Full Text] [Related]
3. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
4. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
5. MUC1 regulates PDGFA expression during pancreatic cancer progression.
Sahraei M; Roy LD; Curry JM; Teresa TL; Nath S; Besmer D; Kidiyoor A; Dalia R; Gendler SJ; Mukherjee P
Oncogene; 2012 Nov; 31(47):4935-45. PubMed ID: 22266848
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.
Besmer DM; Curry JM; Roy LD; Tinder TL; Sahraei M; Schettini J; Hwang SI; Lee YY; Gendler SJ; Mukherjee P
Cancer Res; 2011 Jul; 71(13):4432-42. PubMed ID: 21558393
[TBL] [Abstract][Full Text] [Related]
7. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
Front Oncol; 2019; 9():330. PubMed ID: 31114758
[TBL] [Abstract][Full Text] [Related]
8. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Nath S; Roy LD; Grover P; Rao S; Mukherjee P
Pancreas; 2015 Aug; 44(6):909-17. PubMed ID: 26035123
[TBL] [Abstract][Full Text] [Related]
9. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
[TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
11. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
12. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
[TBL] [Abstract][Full Text] [Related]
13. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
[TBL] [Abstract][Full Text] [Related]
14. Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis.
Hanson RL; Brown RB; Steele MM; Grandgenett PM; Grunkemeyer JA; Hollingsworth MA
Oncotarget; 2016 Jun; 7(26):39996-40011. PubMed ID: 27220889
[TBL] [Abstract][Full Text] [Related]
15. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
[TBL] [Abstract][Full Text] [Related]
17. Immunobiology of human mucin 1 in a preclinical ovarian tumor model.
Budiu RA; Elishaev E; Brozick J; Lee M; Edwards RP; Kalinski P; Vlad AM
Oncogene; 2013 Aug; 32(32):3664-75. PubMed ID: 22964632
[TBL] [Abstract][Full Text] [Related]
18. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.
Curry JM; Thompson KJ; Rao SG; Besmer DM; Murphy AM; Grdzelishvili VZ; Ahrens WA; McKillop IH; Sindram D; Iannitti DA; Martinie JB; Mukherjee P
J Surg Oncol; 2013 Jun; 107(7):713-22. PubMed ID: 23335066
[TBL] [Abstract][Full Text] [Related]
19. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population.
Kidiyoor A; Schettini J; Besmer DM; Rego SL; Nath S; Curry JM; Roy LD; Dréau D; Mukherjee P
Front Immunol; 2014; 5():67. PubMed ID: 24605110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
